Radiofrequency ablation of lung metastases of colorectal cancer: could early radiomics analysis of the ablation zone help detect local tumor progression?


Journal

The British journal of radiology
ISSN: 1748-880X
Titre abrégé: Br J Radiol
Pays: England
ID NLM: 0373125

Informations de publication

Date de publication:
01 Jun 2023
Historique:
medline: 22 5 2023
pubmed: 18 4 2023
entrez: 17 4 2023
Statut: ppublish

Résumé

To determine whether radiomics data can predict local tumor progression (LTP) following radiofrequency ablation (RFA) of colorectal cancer (CRC) lung metastases on the first revaluation chest CT. This case-control single-center retrospective study included 95 distinct lung metastases treated by RFA (in 39 patients, median age: 63.1 years) with a contrast-enhanced CT-scan performed 3 months after RFA. Forty-eight radiomics features (RFs) were extracted from the 3D-segmentation of the ablation zone. Several supervised machine-learning algorithms were trained in 10-fold cross-validation on reproducible RFs to predict LTP, with/without denoising CT-scans. An unsupervised classification based on reproducible RFs was built with k-means algorithm. There were 20/95 (26.7%) relapses within a median delay of 10 months. The best model was a stepwise logistic regression on raw CT-scans. Its cross-validated performances were: AUROC = 0.72 (0.58-0.86), area under the Precision-Recall curve (AUPRC) = 0.44. Cross-validated balanced-accuracy, sensitivity and specificity were 0.59, 0.25 and 0.93, respectively, using Predictive models using RFs from the post-RFA ablation zone on the first revaluation CT-scan of CRC lung metastases seemed moderately informative regarding the occurrence of LTP. Radiomics approach on interventional radiology data is feasible. However, patterns of heterogeneity detected with RFs on early re-evaluation CT-scans seem biased by different healing processes following benign RFA complications.

Identifiants

pubmed: 37066833
doi: 10.1259/bjr.20201371
pmc: PMC10230393
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

20201371

Déclaration de conflit d'intérêts

Conflicts of interestJ.P. has participated in workshops for Boston Scientific. The other authors have no conflicts of interest to declare.

Références

Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Radiology. 2003 Dec;229(3):821-9
pubmed: 14657317
Eur Radiol. 2020 May;30(5):2413-2424
pubmed: 31953663
Cardiovasc Intervent Radiol. 2009 May;32(3):478-83
pubmed: 19127381
Br J Radiol. 2009 Dec;82(984):989-94
pubmed: 19470575
J Magn Reson Imaging. 2010 Jan;31(1):192-203
pubmed: 20027588
Radiology. 2020 May;295(2):328-338
pubmed: 32154773
EBioMedicine. 2019 Oct;48:332-340
pubmed: 31522983
J Magn Reson Imaging. 2020 Jul;52(1):282-297
pubmed: 31922323
Cardiovasc Intervent Radiol. 2021 Jun;44(6):913-920
pubmed: 33506278
Med Phys. 2014 Mar;41(3):033502
pubmed: 24593744
J Nucl Med. 2019 Nov;60(11):1543-1544
pubmed: 31541033
Clinics (Sao Paulo). 2021 Jul 16;76:e2888
pubmed: 34287480
Biostatistics. 2019 Apr 1;20(2):218-239
pubmed: 29325029
Cancer. 1950 Jan;3(1):32-5
pubmed: 15405679
Radiology. 2019 Mar;290(3):783-792
pubmed: 30561278
Cardiovasc Intervent Radiol. 2018 Nov;41(11):1727-1734
pubmed: 29766240
Front Oncol. 2021 Apr 29;11:657039
pubmed: 34026632
Eur Radiol. 2021 Nov;31(11):8302-8314
pubmed: 33954806
Cancer Res. 2018 Aug 15;78(16):4786-4789
pubmed: 29959149
Radiat Oncol. 2017 Sep 25;12(1):158
pubmed: 28946909
Int J Radiat Oncol Biol Phys. 2016 Apr 1;94(5):1121-8
pubmed: 26907916
Comput Methods Programs Biomed. 2018 Jun;159:23-30
pubmed: 29650315
J Med Imaging (Bellingham). 2015 Oct;2(4):041010
pubmed: 26835492
IEEE Trans Med Imaging. 1999 Nov;18(11):1049-75
pubmed: 10661324
J Nucl Med. 2018 Feb;59(2):189-193
pubmed: 29175982
Ann Oncol. 2016 Aug;27(8):1386-422
pubmed: 27380959
Eur J Radiol. 2021 Aug;141:109773
pubmed: 34022475
Eur J Nucl Med Mol Imaging. 2013 Dec;40(12):1817-27
pubmed: 24042540
Cancer. 2006 Dec 15;107(12):2873-80
pubmed: 17096433
J Magn Reson Imaging. 2019 Aug;50(2):497-510
pubmed: 30569552
PLoS One. 2018 Feb 5;13(2):e0192002
pubmed: 29401463
Cardiovasc Intervent Radiol. 2011 Oct;34(5):989-97
pubmed: 21127867
Radiographics. 2012 Jul-Aug;32(4):947-69
pubmed: 22786987
Nat Rev Clin Oncol. 2017 Dec;14(12):749-762
pubmed: 28975929

Auteurs

Amandine Crombé (A)

Department of Diagnostic and Interventional Oncological Imaging, Institut Bergonié, Regional Comprehensive Cancer of Nouvelle-Aquitaine, Bordeaux cedex, France.
Univ. Bordeaux, Bordeaux, France.
Models in Oncology (MONC) team, INRIA Bordeaux Sud-Ouest, Talence, France.

Jean Palussière (J)

Department of Diagnostic and Interventional Oncological Imaging, Institut Bergonié, Regional Comprehensive Cancer of Nouvelle-Aquitaine, Bordeaux cedex, France.
Univ. Bordeaux, Bordeaux, France.

Vittorio Catena (V)

Department of Diagnostic and Interventional Oncological Imaging, Institut Bergonié, Regional Comprehensive Cancer of Nouvelle-Aquitaine, Bordeaux cedex, France.

Maxime Cazayus (M)

Department of Diagnostic and Interventional Oncological Imaging, Institut Bergonié, Regional Comprehensive Cancer of Nouvelle-Aquitaine, Bordeaux cedex, France.

Marianne Fonck (M)

Department of Medical Oncology, Institut Bergonié, Regional Comprehensive Cancer of Nouvelle-Aquitaine, Bordeaux cedex, France.

Dominique Béchade (D)

Department of Medical Oncology, Institut Bergonié, Regional Comprehensive Cancer of Nouvelle-Aquitaine, Bordeaux cedex, France.

Xavier Buy (X)

Department of Diagnostic and Interventional Oncological Imaging, Institut Bergonié, Regional Comprehensive Cancer of Nouvelle-Aquitaine, Bordeaux cedex, France.

Romane Markich (R)

Department of Diagnostic and Interventional Oncological Imaging, Institut Bergonié, Regional Comprehensive Cancer of Nouvelle-Aquitaine, Bordeaux cedex, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH